Retrospective Study on the Features and Outcomes of a Tuscany COVID-19 Hospitalized Patients Cohort: Preliminary Results

Author:

Silvestri Caterina1,Stasi Cristina12ORCID,Profili Francesco1ORCID,Bartolacci Simone1,Sessa Emiliano1,Tacconi Danilo3,Villari Liliana4,Carrozzi Laura5,Dotta Francesco26,Bargagli Elena7ORCID,Donnini Sandra8ORCID,Masotti Luca9,Rasero Laura10,Lavorini Federico11,Pistelli Francesco5ORCID,Chimera Davide5ORCID,Sorano Alessandra11,Pacifici Martina1,Milli Caterina1,Voller Fabio1,

Affiliation:

1. Epidemiology Unit, Regional Health Agency of Tuscany, 50141 Florence, Italy

2. Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy

3. Infectious Diseases Unit, PO San Donato, 52100 Arezzo, Italy

4. Division of Pneumology, AUSL Toscana Nord-Ovest, Apuane Hospital, 54100 Massa, Italy

5. Pneumology Unit, Pisa University Hospital, 56124 Pisa, Italy

6. Diabetes and Metabolic Diseases Unit, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy

7. Respiratory Diseases Unit, Department Medical Sciences, Surgery and Neurological Sciences, Siena University, 53100 Siena, Italy

8. Department of Life Sciences, University of Siena, 53100 Siena, Italy

9. Internal Medicine II and Stroke Unit, San Giuseppe Hospital, 20123 Empoli, Italy

10. Department of Health Sciences, Clinical Innovations and Research Unit, Careggi University Hospital, University of Florence, 50121 Florence, Italy

11. Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy

Abstract

Background: A few months after the COVID-19 pandemic onset, knowledge of SARS-CoV-2 infection and outcomes and treatments blew up. This paper aimed to evaluate the features of a Tuscany COVID-19 hospitalized cohort and to identify risk factors for COVID-19 severity. Methods: This retrospective observational COVID-19 cohort study (1 March 2020–1 March 2021) was conducted on patients ≥ 18 years old, admitted to Tuscany Hospital, and subjected to follow-up within 12 months after discharge. Patients were enrolled at Pisana, Senese and Careggi University Hospitals, and South East, North West, and Center Local Hospitals. Results: 2888 patients (M = 58.5%, mean age = 66.2 years) were enrolled, of whom 14.3% (N = 413) were admitted to an intensive care unit. Smokers were 25%, and overweight and obese 65%. The most used drugs were corticosteroids, antacids, antibiotics, and antithrombotics, all antiviral drugs, with slight differences between 2020 and 2021. A strong association was found between outcomes of evolution towards critical COVID-19 (non-invasive mechanical ventilation (NIV) and/or admission to intensive care) and smoking (RR = 4.91), ex-smoking (RR = 3.48), overweight (RR = 1.30), obese subjects (RR = 1.62), comorbidities (aRR = 1.38). The alteration of liver enzymes (aspartate aminotransferase, alanine aminotransferase, or gamma-glutamyl transpeptidase) was associated with NIV (aOR = 2.28). Conclusions: Our cohort, characterized by patients with a mean age of 66.2 years, showed 65% of patients were overweight and obese. Smoking/ex-smoking, overweight/obesity, and other comorbidities were associated with COVID-19 adverse outcomes. The findings also demonstrated that alterations in liver enzymes were associated with worse outcomes.

Funder

Tuscany Region

Publisher

MDPI AG

Reference41 articles.

1. Salamanna, F., Maglio, M., Landini, M.P., and Fini, M. (2020). Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. Front. Med., 7.

2. World Health Organization (2022, June 17). Interim Statement on Decision-Making Considerations for the Use of Variant Updated COVID-19 Vaccines, Available online: https://www.who.int/news/item/17-06-2022-interim-statement-on-decision-making-considerations-for-the-use-of-variant-updated-covid-19-vaccines.

3. Single-cell multi-omics analysis of the immune response in COVID-19;Stephenson;Nat. Med.,2021

4. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV;Sheahan;Nat. Commun.,2020

5. Compassionate Use of Remdesivir for Patients with Severe COVID-19;Grein;N. Engl. J. Med.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3